Investor Presentation - First Six Months of 2021
49
Investor presentation First six months of 2021
SUSTAIN trials with subcutaneous semaglutide
1
2
3
4
5
6
7
SUSTAIN
8.1%
8.1%
8.3%
8.2%
8.4%
8.7%
8.2%
Baseline
-0.1
-0.4
Change in
HbA1c (%)
-0.5
-0.9
-0.8
-1.1
-1.1
-1.2
-1.3
-01
-1.4
-1.4
-1.5
-1.5
-1.8
-1.8-1.5
-1.6
-1.6
-1.6
1.2
92 kg
89 kg
96 kg
93 kg
92 kg
92 kg
95 kg
Baseline
Change in
weight (kg)
-4.5
-3.7
-1
-1.9
-1.9
semaglutide 1.0 mg
-4.3
-6.1
semaglutide 0.5 mg
-5.6
placebo
-5.2
-1.4
-3.5
-3.7
-3.6
-4.9
sitagliptin 100 mg
-6.4
exenatide ER
glargine U100
-0.7
-6.5
dulaglutide 1.5 mg
-4.6
-2.3
-3.0
dulaglutide 0.75 mg
Novo NordiskⓇ
* Statistically significant; SUSTAIN 1: QW sema vs placebo in drug-naïve people with T2D; SUSTAIN 2: QW sema vs sitagliptin 100 mg QD in people with T2D added to 1-2 OADS; SUSTAIN 3: QW sema vs QW exenatide ER 2.0 mg in people with T2D added to 1-2
OADS; SUSTAIN 4: QW sema vs QD insulin glargine in people with T2D added to 1-2 OADS; SUSTAIN 5: QW sema vs placebo in people with T2D added to insulin; SUSTAIN 6: QW sema vs placebo, added to standard-of-care; SUSTAIN 7: QW sema vs QW dulaglutide
75 mg and 150 mg in people with T2D added to 1-2 OADS: ER: Extended-release; QW: once weekly; QD: once daily; sema: semaglutide; T2D: type 2 diabetes, OAD: oral anti-diabeticsView entire presentation